This technology involves treating adipose-derived stem cells with udenafil during culture to enhance their hair growth-promoting capabilities. It also covers hair loss improvement compositions containing the resulting adipose-derived stem cells, their culture medium, or the cytokines increased within those cells as active ingredients.
While minoxidil and finasteride are the standard approved drugs for hair growth, they are associated with side effects such as systemic hair growth and sexual dysfunction, and their mechanisms of action remain unclear. Although adipose-derived stem cells have been reported to induce hair regeneration, methods to significantly enhance their hair growth-promoting potential have been limited.
This technology leverages the fact that udenafil-stimulated adipose-derived stem cells show increased expression of IL-4 and IL-12B, cytokines that promote hair follicle maturation and demonstrate significantly higher hair growth effects compared to untreated stem cells. Since applying IL-4 and IL-12B directly to the skin also induces hair growth, this can be expanded into cell-free formulations. It can be applied to the development of stem cell culture-based scalp ampoules, hair loss treatments, and cell therapy materials, providing an alternative ingredient that reduces the burden of side effects associated with existing hair loss medications.
CN110548031B, US11608490B2
